Commercial Lilly falls on slower start for Foundayo versus Wegovy PharmaphorumSky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.Metabolic & GLP-1Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaphorum Sky-high expectations for sales of Eli Lilly’s new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA. Metabolic & GLP-1 Read full story Post navigation Previous: UK biotech could be bound for recovery, BIA report revealsNext: New NIHR-funded TRC for Parkinson’s disease Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026